Delayed Quote. Delayed  - 05/12 11:32:00 am
1.45CHF -2.03%

Press Release: Addex to Present at the 20th Annual Needham Virtual Healthcare Conference

04/13/2021 | 01:00am
   Geneva, Switzerland, April 13, 2021 - 
Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage 
pharmaceutical company pioneering allosteric modulation-based drug 
discovery and development, announced today that Tim Dyer, Chief 
Executive Officer, will present at the 
20th Annual Needham Virtual Healthcare Conference (April 12-15, 2021). 
   In his presentation, which is scheduled for Tuesday, April 13, 2021 at 
08:00 EST, Mr Dyer will provide a corporate update and discuss recent 
developments at Addex. The video presentation will be available for 
viewing on-demand by registered participants via this 
link from the time of the presentation and subsequently on the 
Events page of the Company's website ( 
   Management will be available for virtual one-on-one meetings throughout 
the conference. For more information or to schedule a one-on-one meeting 
with management, please contact your conference representative or 
   About Addex Therapeutics: 
Addex Therapeutics is a clinical-stage pharmaceutical company focused on 
the development and commercialization of an emerging class of novel 
orally available small molecule drugs known as allosteric modulators for 
neurological disorders. Allosteric modulators offer several potential 
advantages over conventional non-allosteric molecules and may offer an 
improved therapeutic approach to conventional "orthosteric" small 
molecule or biological drugs. Adder's allosteric modulator drug 
discovery platform targets receptors and other proteins that are 
recognized as essential for therapeutic intervention. adder's lead drug 
candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is 
poised to start a pivotal registration clinical trial for Parkinson's 
disease levodopa induced dyskinesia (PD-LID) in Q2 2021. Addex is also 
investigating dipraglurant's therapeutic use in blepharospasm (a type of 
dystonia), for which a clinical trial is expected to be initiated in Q2 
2021. Addex's third clinical program, ADX71149 (mGlu2 positive 
allosteric modulator or PAM), developed in collaboration with Janssen 
Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept 
clinical study for the treatment of epilepsy in Q2 2021. Addex's GABAB 
PAM program has been licensed to Indivior PLC who are focused on 
development for the treatment of addiction. Preclinical programs include 
GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild 
neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 
PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss 
Exchange and the NASDAQ Capital Market and trades under the ticker 
symbol "ADXN". 
   Press Contacts: 
Tim Dyer                          Mike Sinclair                 James Carbonara 
 Chief Executive Officer           Partner, Halsin Partners      Hayden IR 
 +41 22 884 15 55                  +44 (0) 20 7318 2955          (646)-755-7412 
--------------------------------  ----------------------------  -------------------------- 
   Forward Looking Statements: 
   This press release contains forward-looking statements within the 
meaning of the Private Securities Litigation Reform Act of 1995, as 
amended, including in respect of the anticipated initiation of clinical 
trials. The words "may," "will," "could," "would," "should," "expect," 
"plan," "anticipate," "intend," "believe," "estimate," "predict," 
"project," "potential," "continue," "target" and similar expressions are 
intended to identify forward-looking statements, although not all 
forward-looking statements contain these identifying words. Any 
forward-looking statements in this press release, are based on 
management's current expectations and beliefs and are subject to a 
number of risks, uncertainties and important factors that may cause 
actual events or results to differ materially from those expressed or 
implied by any forward-looking statements contained in this press 
release, including, without limitation, uncertainties related to market 
conditions. These and other risks and uncertainties are described in the 
Company's Annual Report on Form 20-F filed with the SEC on March 11, 
2021, as well as market conditions and regulatory review. 
   Any forward-looking statements contained in this press release represent 
Addex Therapeutics' views only as of the date hereof and should not be 
relied upon as representing its views as of any subsequent date. Addex 
Therapeutics explicitly disclaims any obligation to update any 
forward-looking statements. 

(END) Dow Jones Newswires

April 13, 2021 01:00 ET (05:00 GMT)

Copier lien